CAMP4 Therapeutics Corporation (CAMP)
Last Price$5.3(1.1%)
Market Cap$196.5M
CAMP Rating
CAMP Quality rating performance
CAMP Intrinsic Value
Key Highlights:
As of Mar 18, 2025 CAMP Relative Value is $18.9, which is undervalued by 256.7%, compared to current share price of $5.3.
As of Mar 18, 2025 CAMP DCF Value is N/A, which is undervalued by N/A, compared to current share price of $5.3.
CAMP Share Price History
1W (3.3%)
1M 11.8%
6M (50.5%)
YTD (10.9%)
1Y 81.2%
3Y (96.9%)
5Y (95.1%)
10Y (98.7%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
CAMP Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$196.5M
$400.2M
$264.7M
($3,080.0K)
Shares Outstanding
37M
Employees
N/A
Growth (CAGR)
(6.7%)
N/A
23.0%
(16.67%)
Profitability
35.8%
(34.3%)
(38.3%)
1.9%
(1.2%)
3.0%
Intrinsic Value
$19.3 (262.6% undervalued)
N/A
$19.3
(100.0%)
(414.9%)
Valuation (LTM)
Return on Capital
Financial Health
$203.7M
(66.2x)
(14.5x)
(326.3%)
Dividends
Earnings
Jan 01, 1970
MISS by (134.1%)
BEAT by (7.9%)
(9.5%)
5 Beat & 5 Miss
CAMP Stock Financials
CAMP Income Statement Metrics
Annual
Quarterly
LTM
CAMP Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
N/A N/A YoY
Capital Expenditure (CAPEX)
N/A -34.8% YoY
Free Cash Flow (FCF)
N/A -92.6% YoY
CAMP Income Statement Overview
Annual
Quarterly
LTM
Feb'15
Feb'16
Feb'17
Feb'18
Feb'19
Feb'20
Feb'21
Feb'22
Feb'23
Nov'23
$186.2M (36.9%) YoY
Cost of revenue
$119.3M (35.9%) YoY
Operating
expenses
$75.7M (41.4%) YoY
Other: $93.3M
CAMP Balance Sheet Overview
Annual
Quarterly
LTM
Feb'15
Feb'16
Feb'17
Feb'18
Feb'19
Feb'20
Feb'21
Feb'22
Feb'23
Nov'23
Assets
Liabilities
Total assets
N/A
Current assets (N/A, N/A of total)
Non-current assets (N/A, N/A of total)
N/A (N/A)
N/A (N/A)
N/A (N/A)
Other non-current assets
N/A (N/A)
Financial position
$0.0
Cash & Short-term
Investments
Total Debt
CAMP Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
CAMP Earnings Surprises
Crunching data... Almost there!
CAMP Dividends
CAMP Dividend Yield
Crunching data... Almost there!
CAMP Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with CAMP
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$196.5M | 5.2 | $19.3 262.6% undervalued | 81.2% | $264.7M | ($3,080.0K) | (7.1%) | (1.2%) | 35.8% | (51.9%) | (326.3%) | |
$132.4B | 5.8 | $185.4 63.8% overvalued | 24.5% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$72.4B | 6.4 | $1,022.8 53.8% undervalued | (30.6%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$36.9B | 6.3 | $189.5 69.0% overvalued | 69.0% | $3,154.8M | ($58.8M) | 157.1% | (1.9%) | 74.8% | 67.0% | 0.7% | |
$32.2B | 5.2 | $90.9 62.8% overvalued | 65.7% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$23.9B | 5.9 | $195.6 97.7% undervalued | 6.4% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$14.9B | 5.5 | $69.3 107.5% undervalued | 14.6% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$14.6B | 6.0 | $0.6 97.1% overvalued | 381.6% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.4B | 7.8 | $529.4 68.5% undervalued | 34.3% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.7B | 6.8 | $49.6 30.6% overvalued | (14.7%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$1,846.9M | 5.5 | $2,609.6 1,051.1% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
FAQ
What is CAMP4 Therapeutics Corporation (CAMP) stock rating?
As of today, CAMP4 Therapeutics Corporation has a stock rating of 5 (out of 10), which is considered Good.
is CAMP4 Therapeutics Corporation (CAMP) a good stock to buy?
As of today, CAMP4 Therapeutics Corporation has a Good stock rating, which is 262.6% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.